Rationale for the EUCAST clinical breakpoints

First Page		Document Content
Date: 2012-01-12 15:20:36 Biology Chemistry Antifungals Amphotericin B Aspergillus fumigatus		Rationale for the EUCAST clinical breakpoints Add to Reading List Source URL: www.eucast.org Download Document from Source Website File Size: 241,13 KB Share Document on Facebook

	ismp-hosp-temp-MASTER.qxd DocID: 1qIK8 - View Document
	article published online: 1 june 2015 \| doi: nchembio.1821 Nontoxic antimicrobials that evade drug resistance Stephen A Davis1,2, Benjamin M Vincent3,4, Matthew M Endo1,2, Luke Whitesell4, Karen Marchillo5,6, Dav DocID: 1pvkH - View Document
	PRESS RELEASE F2G Ltd announces the appointment of Ralf Schmid to the position of Chief Financial Officer MANCHESTER, UK – 11 JulyF2G Ltd, the UK-based antifungal drug discovery and development company, today a DocID: 1oWNB - View Document
	Report 2014 Aspergillus working group DocID: 1o3re - View Document
	Amphotericin B Analogs Boast Lower Toxicity \| June 8, 2015 Issue Vol. 93 Issue 23 \| Chemical & Engineering News DocID: 1gOcD - View Document